The Pathway to Proof-of-Concept for BNC210, a Negative Allosteric Modulator of the Alpha-7 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric Disease.

The rationale for developing a negative allosteric modulator is that there may be significant inhibition of the α7 pathway with a modulator under high states of arousal, such as in anxiety and stress‐related disorders, whereas under basal states, there would be less inhibition.

also in 13,097 other papers